Literature DB >> 34907257

Immunoreactivity of the SARS-CoV-2 entry proteins ACE-2 and TMPRSS-2 in murine models of hormonal manipulation, ageing, and cardiac injury.

Susan Bengs1,2, Alexia Rossi1,2, Vera Regitz-Zagrosek3,4, Catherine Gebhard5,6,7, Martina Haberecker8, Nidaa Mikail1,2, Alexander Meisel1,2, Ahmed Haider9, Muriel Grämer1,2, Angela Portmann1,2, Atanas Todorov1,2, Christof Schönenberger10, Caroline E Gebhard10, Gabriela M Kuster11,12.   

Abstract

Previous work indicates that SARS-CoV-2 virus entry proteins angiotensin-converting enzyme 2 (ACE-2) and the cell surface transmembrane protease serine 2 (TMPRSS-2) are regulated by sex hormones. However, clinical studies addressing this association have yielded conflicting results. We sought to analyze the impact of sex hormones, age, and cardiovascular disease on ACE-2 and TMPRSS-2 expression in different mouse models. ACE-2 and TMPRSS-2 expression was analyzed by immunostaining in a variety of tissues obtained from FVB/N mice undergoing either gonadectomy or sham-surgery and being subjected to ischemia-reperfusion injury or transverse aortic constriction surgery. In lung tissues sex did not have a significant impact on the expression of ACE-2 and TMPRSS-2. On the contrary, following myocardial injury, female sex was associated to a lower expression of ACE-2 at the level of the kidney tubules. In addition, after myocardial injury, a significant correlation between younger age and higher expression of both ACE-2 and TMPRSS-2 was observed for lung alveoli and bronchioli, kidney tubules, and liver sinusoids. Our experimental data indicate that gonadal hormones and biological sex do not alter ACE-2 and TMPRSS-2 expression in the respiratory tract in mice, independent of disease state. Thus, sex differences in ACE-2 and TMPRSS-2 protein expression observed in mice may not explain the higher disease burden of COVID-19 among men.
© 2021. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34907257      PMCID: PMC8671541          DOI: 10.1038/s41598-021-03181-3

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Introduction

As of June 2021, the coronavirus disease (COVID)-19 pandemic has caused more than 175 Mio infections and 3.7 Mio deaths worldwide. Pre-existing cardiovascular disease (CVD) has been identified as predominant risk factor for a poor prognosis in COVID-19 patients[1-3]. Suggested mechanisms accounting for this association involve the SARS-CoV-2 entry proteins angiotensin-converting enzyme 2 (ACE-2) and transmembrane protease serine 2 (TMPRSS-2). Emerging data support the hypothesis that the expression of these entry proteins is increased in patients with CVD, particularly in cardiomyocytes[4]. As such, recent results demonstrated that patients with non-ischemic dilated cardiomyopathy, hypertrophic cardiomyopathy, and aortic stenosis exhibit increased expression of ACE-2[5,6] and that TMPRSS-2 expression increases with age and in males[7], all of which have been associated with adverse outcomes in COVID-19[3,8,9]. Animal models of gonadectomy showing that estrogen and testosterone exert opposite effects on myocardial ACE-2 expression further support a sexual dimorphism in SARS-CoV-2 entry protein regulation[10]. Despite this, clinical studies addressing the role of sex as well as sex hormones and regulation of ACE-2 and TMPRSS-2 in COVID-19 patients are scarce and the few studies available have yielded conflicting results. While initial reports identified a link between the androgen-mediated phenotype of androgenetic alopecia and COVID-19 disease severity[11,12] as well as a reduced COVID-19 incidence or disease burden in men receiving anti-androgenic treatment[13-15], more recent data have refuted this association[16-19]. Also, new results point towards a bivalent role of testosterone in COVID-19 as lower serum testosterone levels predicted poor prognosis and mortality in critically ill men infected with SARS-CoV-2[20,21]. In women, a study from Wuhan, China, demonstrated that higher anti-Müllerian hormone or estradiol levels were associated with a mild COVID-19 disease course in 78 female patients[22], and a retrospective analysis of 68′466 electronic health records reported a reduction of COVID-19 fatality risk by 50% in 439 postmenopausal women receiving hormone replacement (HR) therapy[23]. Conversely, preliminary data from the UK-based COVID Symptom Study indicate that HR therapy was positively associated with COVID-19 severity[24], and no increased risk of COVID-19 related mortality was seen in women with gynecologic cancers[25]. Finally, in vitro as well as clinical data showed a reduction of SARS-CoV-2 infection by selective estrogen receptor modulators, but not by agonists/antagonists of estrogen, androgens, or progesterone[26,27]. Given the paucity of data on ACE-2 and TMPRSS-2 protein expression and their interaction with comorbid health conditions and age, we sought to analyze whether sex hormones, age, and CVD impact ACE-2 and TMPRSS-2 expression in murine models.

Method

Study objectives

The ACE-2 receptor is expressed on different types of cells and tissues including human airway epithelia, lung parenchyma, vascular endothelia, renal tubulointerstitial and glomerular cells, central nervous system cells, and small intestinal cells. However, SARS-CoV-2 primarily infects airway epithelial cells. Therefore, the primary objective of our study was to assess whether ACE-2 and TMPRSS-2 expression in lung tissue is regulated by sex, sex hormones, and age at baseline and following myocardial injury. Secondary aims comprised (1) the assessment of ACE-2 and TMPRSS-2 expression in renal and hepatic tissues, and (2) the evaluation of the impact of chronic pressure overload and female reproductive history on ACE-2 and TMPRSS-2 expression in lung, kidney, and liver tissues.

Mouse models

ACE-2 and TMPRSS-2 expression was analyzed in female and male FVB/N mice (Janvier Labs, France) at different ages (4 months [young], 12 months [middle-aged], and 20–22 months [aged]), with either intact or different hormonal status, as well as different CVD states. All animals were housed in individually ventilated cages with ad libitum access to water and food, and under specific pathogen-free conditions. To test our hypothesis, experimental models of acute myocardial injury (ischemia-reperfusion model) and chronic pressure overload of the left ventricle (LV) as well as evaluation of female mice reproductive history were employed.

Acute myocardial injury model

Before surgery, mice were randomly assigned to either gonadectomy (Gx) or sham-surgery at the age of 4 weeks, before reaching sexual maturity. Following gonadectomy, mice were randomized to different experimental groups and 90-days sex HR pellets (in Gx + HR mice) or corresponding vehicle controls (in Gx mice) were implanted. For this purpose, either 0.18 mg of 17β-estradiol or 12.5 mg of testosterone pellets (Innovative Research of America, Sarasota, FL, U.S.) were implanted subcutaneously via a 3 mm incision on the dorsal neck. The pellets were renewed every 90-days under isoflurane anesthesia until final assessment to ensure stable long-term hormone treatment. Subgroups of young and aged mice underwent ischemia–reperfusion injury by inducing transient (30 min) ligation of the left anterior descending artery. Organs were harvested after 24 h of reperfusion. A detailed description of the surgical procedure is reported in the Supplementary Information.

Chronic pressure overload model

Young FVB/N mice with intact hormonal status underwent transverse aortic constriction (TAC) or sham surgery to induce persistent pressure overload of the left LV over a total observational time of 28 days. A detailed description of the surgical procedure is reported in the Supplementary Information. The development of pressure overload of the LV was verified by cardiovascular magnetic resonance imaging on a Bruker BioSpec 70/30 USR magnetic resonance scanner in all mice (data available upon request).

Female reproductive history

To assess the potential effect of multiple pregnancies on ACE-2 and TMPRSS-2 expression, tissues of female FVB/N breeders [multiparous] and non-breeders [nulliparous] at the age of 12 months were evaluated. After harvesting, organs were stored at 4 °C in 4% buffered formaldehyde until further analysis. Blood samples were obtained by cardiac puncture and centrifuged at 10,000g for 10 min. The resulting serum samples were snap frozen and stored at − 80 °C until further analysis. All experimental protocols were reviewed and approved by the Commission on Animal Experimentation of the Canton of Zurich and the Cantonal Veterinary Office (link: Application and authorization (admin.ch); license number ZH207/16 and ZH079/18), were carried out in accordance with relevant guidelines and regulations, and reported in accordance with ARRIVE guidelines.

Serum and tissue analysis

Serum sex hormone and soluble ACE-2 (sACE-2) levels were measured using mouse/rat ELISA assays (Calbiotech Inc., El Cajon, CA, U.S and Cloud-Clone Corp., Katy, TX, U.S, respectively) according to the manufacturer’s recommendation. Immunohistochemical stains were performed on formalin-fixed and paraffin embedded tissue using a Bond RX Platform. Immunostainings were performed with established antibodies against the following proteins and visualized using the Bond™ Polymer Refine Detection kit (Leica Biosystems Inc., Buffalo Grove, IL, U.S.): ACE-2; 1:500 dilution (Abcam, #239924) and TMPRSS-2, 1:2,000 dilution (Abcam, #92323). Incubation times were 30 min, respectively, at room temperature. The level of immunoreactivity of ACE-2 and TMPRSS-2 were scored semi-quantitatively (0 = negative; 1 = low; 2 = moderate; 3 = high, Fig. 1A,B). Only membranous staining was evaluated. Additionally, a pattern-based scoring approach was used to evaluate expression levels on liver sinusoids (0 = negative; 1 = portal sinusoids only; 2 = extension to periportal area; 3 = porto-portal/septal pattern). At hepatic level, only the expression of ACE-2 was evaluated since tissue sections were uninterpretable for TMPRSS-2 assessment.
Figure 1

Scoring examples of ACE-2 (upper row) and TMPRSS-2 (lower row) in lung alveoli (A) and lung bronchioli (B). From left to right: Score = 1 (low immunoreactivity), score = 2 (moderate immunoreactivity), score = 3 (high immunoreactivity). Only membranous staining was evaluated. ACE-2, angiotensin-converting enzyme 2; TMPRSS-2, transmembrane protease serine 2.

Scoring examples of ACE-2 (upper row) and TMPRSS-2 (lower row) in lung alveoli (A) and lung bronchioli (B). From left to right: Score = 1 (low immunoreactivity), score = 2 (moderate immunoreactivity), score = 3 (high immunoreactivity). Only membranous staining was evaluated. ACE-2, angiotensin-converting enzyme 2; TMPRSS-2, transmembrane protease serine 2.

Statistical analysis

Data are presented as median (interquartile range) for immunostaining and mean ± standard error of the mean (SEM) for serum analyses. For continuous variables prior to analyses, basic assumptions including normal distribution and homogeneity of variances were checked. Unpaired Student’s t-test, Mann–Whitney test, analysis of variance (ANOVA), or Kruskal–Wallis test were used for group comparisons of serum samples. Mann–Whitney test was performed to compare ACE-2 and TMPRSS-2 immunoreactivity between breeders and non-breeders. Ordinal logistic regression was used to evaluate the impact of age, sex, and type of hormonal status on the different levels of expression of ACE-2 and TMPRSS-2 in the different tissues. Statistical tests were two-sided, and significance was set at p < 0.05. Statistical analyses were performed with IBM SPSS statistics v25.0 and R software[28].

Results

ACE-2 and TMPRSS-2 expression were assessed in different organs and tissues including lung (alveoli and bronchioli), kidney tubules, and liver sinusoids (Tables 1, 2, 3).
Table 1

Impact of age, sex and hormone deprivation/replacement status on ACE-2 and TMPRSS-2 expression at baseline condition.

TissueYoung miceAged miceOrdinal logistic regression(b coefficient and p-value)
ControlGxGx + HRControlGxGx + HR
Females(n = 9)Males(n = 9)Females(n = 10)Males(n = 10)Females(n = 10)Males(n = 10)Females(n = 10)Males(n = 10)Females(n = 10)Males(n = 10)Females(n = 7)Males(n = 7)Age(ref. aged)Sex(ref. males)Gx(ref. control)Gx + HR(ref. control)
ACE-expression
Lungs
 Alveoli

1.00

(1.00–2.00)

1.00

(1.00–2.00)

1.00

(1.00–2.00)

1.00

(1.00–2.00)

1.00

(1.00–2.00)

1.00

(1.00–2.00)

1.00

(1.00–1.00)

1.00

(1.00–2.00)

1.00

(1.00–1.00)

1.00

(1.00–1.25)

1.00

(1.00–2.00)

1.00

(1.00–2.00)

0.516

(0.225)

− 0.317

(0.450)

− 0.625

(0.228)

− 0.029

(0.954)

 Bronchioli

2.00

(2.00–2.00)

2.00

(2.00–2.00)

2.00

(2.00–2.00)

2.00

(2.00–2.00)

2.00

(2.00–2.00)

2.00

(2.00–2.00)

2.00

(1.25–2.00)

2.00

(2.00–2.00)

2.00

(1.25–2.00)

2.00

(1.75–2.00)

2.00

(2.00–2.00)

2.00

(1.00–2.00)

2.766

(0.010)

− 0.085

(0.895)

− 0.0115

(0.884)

− 0.399

(0.616)

Kidneys
 Tubules

2.00

(1.00–2.50)

2.00

(2.00–2.25)

2.00

(1.75–3.00)

2.00

(2.00–2.00)

2.00

(1.75–2.25)

2.00

(2.00–3.00)

2.00

(1.00–2.00)

2.00

(1.00–2.00)

2.00

(1.50–2.50)

2.00

(1.00–2.00)

1.00

(1.00–2.00)

2.00

(1.00–3.00)

1.192

(0.004)

− 0.425

(0.269)

0.363

(0.430)

0.169

(0.723)

Liver
 Sinusoids

2.00

(2.00–3.00)

2.50

(2.00–3.00)

2.00

(1.75–2.25)

2.00

(2.00–3.00)

2.00

(1.00–2.00)

3.00

(2.00–3.00)

1.00

(1.00–1.25)

1.00

(1.00–1.00)

1.00

(1.00–1.00)

1.00

(1.00–1.25)

1.00

(1.00–1.00)

1.00

(1.00–1.00)

4.225

(< 0.001)

− 1.142

(0.012)

− 0.332

(0.529)

− 0.369

(0.494)

TMPRSS-2 expression
Lungs
 Alveoli

2.00

(1.00–2.00)

1.00

(1.00–2.00)

1.00

(1.00–2.00)

1.00

(1.00–2.00)

1.50

(1.00–2.00)

1.50

(1.00–2.00)

1.00

(1.00–1.00)

1.00

(1.00–2.00)

1.00

(1.00–1.00)

1.00

(1.00–1.00)

1.00

(1.00–2.00)

1.00

(1.00–1.00)

1.671

(0.001)

0.119

(0.790)

− 0.538

(0.330)

− 0.008

(0.988)

 Bronchioli

2.00

(2.00–2.00)

2.00

(2.00–2.00)

2.00

(1.00–2.00)

2.00

(1.00–2.00)

2.00

(1.00–2.00)

2.00

(2.00–2.00)

1.00

(1.00–1.25)

1.00

(1.00–1.00)

1.00

(1.00–1.00)

1.00

(1.00–1.00)

1.00

(1.00–2.00)

1.00

(1.00–1.00)

3.250

(< 0.001)

− 0.235

(0.642)

− 0.996

(0.116)

− 0.340

(0.596)

Kidneys
 Tubules

2.00

(1.00–2.50)

2.00

(2.00–2.00)

2.00

(1.75–2.25)

2.00

(2.00–3.00)

2.00

(1.75–2.00)

2.00

(2.00–2.00)

2.00

(1.75–2.00)

2.50

(2.00–3.00)

2.00

(2.00–2.00)

2.00

(1.00–2.00)

1.00

(1.00–2.00)

2.00

(1.00–2.00)

0.329

(0.396)

− 0.986

(0.014)

− 0.442

(0.342)

− 0.853

(0.080)

Liver
 SinusoidsUninterpretable tissue sections

Data are expressed as median (interquartile range). P-values were derived from ordinal logistic regression.

Significant values are in bold. ACE-2, angiotensin-converting enzyme 2; Gx, gonadectomy; HR, hormone replacement; TMPRSS-2, transmembrane protease serine 2.

Table 2

Impact of age, sex and hormone deprivation/replacement status on ACE-2 and TMPRSS-2 expression after acute myocardial injury.

TissueYoung miceAged miceOrdinal logistic regression(b coefficient and p-value)
ControlGxGx + HRControlGxGx + HR
Females(n = 10)Males(n = 10)Females(n = 10)Males(n = 10)Females(n = 10)Males(n = 9)Females(n = 8)Males(n = 9)Females(n = 10)Males(n = 10)Females(n = 3)Males(n = 5)Age(ref. aged)Sex(ref. males)Gx(ref. control)Gx + HR(ref. control)
ACE-expression
Lungs
 Alveoli

2.50

(2.00–3.00)

2.00

(2.00–3.00)

2.50

(2.00–3.00)

3.00

(2.75–3.00)

2.00

(1.00–3.00)

2.00

(2.00–3.00)

2.00

(2.00–2.00)

2.00

(1.50–3.00)

2.00

(1.75–3.00)

2.00

(1.75–3.00)

2.00

(1.00–)

2.00

(2.00–3.00)

0.787

(0.044)

− 0.392

(0.300)

0.479

(0.279)

− 0.167

(0.731)

 Bronchioli

2.00

(2.00–3.00)

2.00

(2.00–2.25)

3.00

(2.00–3.00)

3.00

(3.00–3.00)

2.00

(2.00–2.00)

2.00

(2.00–3.00)

2.00

(2.00–2.75)

2.00

(1.50–3.00)

2.00

(1.75–3.00)

2.00

(1.00–3.00)

2.00

(2.00–2.00)

2.00

(2.00–3.00)

0.851

(0.035)

− 0.305

(0.431)

0.874

(0.055)

− 0.188

(0.706)

Kidneys
 Tubules

2.00

(1.00–2.00)

2.00

(1.00–2.25)

2.00

(2.00–3.00)

2.00

(2.00–3.00)

1.50

(1.00–3.00)

2.00

(2.00–3.00)

1.00

(1.00–2.00)

2.00

(2.00–3.00)

1.00

(1.00–2.00)

1.00

(1.00–2.00)

1.00

(1.00–)

2.00

(2.00–2.50)

1.047

(0.009)

− 1.082

(0.006)

0.143

(0.747)

0.289

(0.555)

Liver
 Sinusoids

2.00

(2.00–2.00)

2.00

(1.00–2.00)

1.00

(1.00–2.00)

1.50

(1.00–2.25)

1.00

(1.00–1.00)

1.50

(1.00–2.25)

1.00

(1.00–1.00)

1.00

(1.00–1.00)

1.00

(0.00–1.00)

1.00

(0.75–1.00)

0.00

(0.00–0.00)

1.00

(1.00–2.00)

3.667

(< 0.001)

− 0.839

(0.054)

− 1.082

(0.039)

− 1.383

(0.014)

TMPRSS-2 expression
Lungs
 Alveoli

2.00

(2.00–2.25)

2.00

(1.75–3.00)

2.00

(2.00–2.25)

2.00

(1.75–2.00)

2.00

(2.00–3.00)

2.00

(2.00–3.00)

2.00

(1.00–2.00)

2.00

(1.00–2.00)

1.50

(1.00–2.00)

2.00

(1.75–2.00)

2.00

(2.00–)

2.00

(1.50–2.00)

1.836

(< 0.001)

− 0.039

(0.924)

− 0.417

(0.393)

1.062

(0.054)

 Bronchioli

2.00

(1.75–2.25)

2.00

(2.00–3.00)

2.00

(1.75–2.00)

2.00

(1.75–2.00)

2.00

(2.00–2.00)

2.00

(2.00–3.00)

2.00

(1.00–2.00)

2.00

(1.00–2.00)

2.00

(1.00–2.25)

2.00

(1.00–2.00)

2.00

(2.00–2.00)

2.00

(1.00–2.00)

1.054

(0.014)

− 0.287

(0.473)

− 0.229

(0.621)

0.373

(0.475)

Kidneys
 Tubules

2.00

(1.75–2.00)

2.00

(1.75–3.00)

2.00

(2.00–2.25)

2.00

(2.00–3.00)

2.00

(2.00–3.00)

2.00

(2.00–3.00)

2.00

(1.00–2.00)

2.00

(2.00–2.00)

2.00

(1.00–2.00)

2.00

(1.00–2.00)

2.00

(2.00–2.00)

2.00

(1.50–2.00)

1.287

(0.005)

− 0.358

(0.381)

0.415

(0.385)

0.516

(0.330)

Liver
 SinusoidsUninterpretable tissue sections

Data are expressed as median (interquartile range). P-values were derived from ordinal logistic regression.

Significant values are in bold. ACE-2, angiotensin-converting enzyme 2; Gx, gonadectomy; HR, hormone replacement; TMPRSS-2, transmembrane protease serine 2.

Table 3

Impact of female reproductive history on ACE-2 and TMPRSS-2 expression.

TissueNulliparous(n = 8)Multiparous(n = 10)p-values
ACE-2 expression
Lungs
 Alveoli1.00 (1.00–1.00)1.00 (1.00–1.00)1.000
 Bronchioli2.00 (1.00–2.00)2.00 (1.00–2.00)0.796
Kidneys
 Tubules2.00 (1.00–2.00)2.00 (2.00–2.00)0.573
Liver
 Sinusoids1.00 (1.00–1.00)1.00 (1.00–1.25)0.515
TMPRSS-2 expression
Lungs
 Alveoli1.00 (1.00–1.00)1.00 (1.00–1.00)1.000
1.00 (1.00–1.00)1.00 (1.00–1.00)0.439
Kidneys
 Tubules2.00 (2.00–2.00)2.00 (1.75–2.00)0.929
Liver
 SinusoidsUninterpretable tissue sections

Data are expressed as median (interquartile range). P-values were derived from Mann–Whitney test. ACE-2, angiotensin-converting enzyme 2; TMPRSS-2, transmembrane protease serine 2.

Impact of age, sex and hormone deprivation/replacement status on ACE-2 and TMPRSS-2 expression at baseline condition. 1.00 (1.00–2.00) 1.00 (1.00–2.00) 1.00 (1.00–2.00) 1.00 (1.00–2.00) 1.00 (1.00–2.00) 1.00 (1.00–2.00) 1.00 (1.00–1.00) 1.00 (1.00–2.00) 1.00 (1.00–1.00) 1.00 (1.00–1.25) 1.00 (1.00–2.00) 1.00 (1.00–2.00) 0.516 (0.225) − 0.317 (0.450) − 0.625 (0.228) − 0.029 (0.954) 2.00 (2.00–2.00) 2.00 (2.00–2.00) 2.00 (2.00–2.00) 2.00 (2.00–2.00) 2.00 (2.00–2.00) 2.00 (2.00–2.00) 2.00 (1.25–2.00) 2.00 (2.00–2.00) 2.00 (1.25–2.00) 2.00 (1.75–2.00) 2.00 (2.00–2.00) 2.00 (1.00–2.00) 2.766 (0.010) − 0.085 (0.895) − 0.0115 (0.884) − 0.399 (0.616) 2.00 (1.00–2.50) 2.00 (2.00–2.25) 2.00 (1.75–3.00) 2.00 (2.00–2.00) 2.00 (1.75–2.25) 2.00 (2.00–3.00) 2.00 (1.00–2.00) 2.00 (1.00–2.00) 2.00 (1.50–2.50) 2.00 (1.00–2.00) 1.00 (1.00–2.00) 2.00 (1.00–3.00) 1.192 (0.004) − 0.425 (0.269) 0.363 (0.430) 0.169 (0.723) 2.00 (2.00–3.00) 2.50 (2.00–3.00) 2.00 (1.75–2.25) 2.00 (2.00–3.00) 2.00 (1.00–2.00) 3.00 (2.00–3.00) 1.00 (1.00–1.25) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.25) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 4.225 (< 0.001) − 1.142 (0.012) − 0.332 (0.529) − 0.369 (0.494) 2.00 (1.00–2.00) 1.00 (1.00–2.00) 1.00 (1.00–2.00) 1.00 (1.00–2.00) 1.50 (1.00–2.00) 1.50 (1.00–2.00) 1.00 (1.00–1.00) 1.00 (1.00–2.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–2.00) 1.00 (1.00–1.00) 1.671 (0.001) 0.119 (0.790) − 0.538 (0.330) − 0.008 (0.988) 2.00 (2.00–2.00) 2.00 (2.00–2.00) 2.00 (1.00–2.00) 2.00 (1.00–2.00) 2.00 (1.00–2.00) 2.00 (2.00–2.00) 1.00 (1.00–1.25) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–2.00) 1.00 (1.00–1.00) 3.250 (< 0.001) − 0.235 (0.642) − 0.996 (0.116) − 0.340 (0.596) 2.00 (1.00–2.50) 2.00 (2.00–2.00) 2.00 (1.75–2.25) 2.00 (2.00–3.00) 2.00 (1.75–2.00) 2.00 (2.00–2.00) 2.00 (1.75–2.00) 2.50 (2.00–3.00) 2.00 (2.00–2.00) 2.00 (1.00–2.00) 1.00 (1.00–2.00) 2.00 (1.00–2.00) 0.329 (0.396) − 0.986 (0.014) − 0.442 (0.342) − 0.853 (0.080) Data are expressed as median (interquartile range). P-values were derived from ordinal logistic regression. Significant values are in bold. ACE-2, angiotensin-converting enzyme 2; Gx, gonadectomy; HR, hormone replacement; TMPRSS-2, transmembrane protease serine 2. Impact of age, sex and hormone deprivation/replacement status on ACE-2 and TMPRSS-2 expression after acute myocardial injury. 2.50 (2.00–3.00) 2.00 (2.00–3.00) 2.50 (2.00–3.00) 3.00 (2.75–3.00) 2.00 (1.00–3.00) 2.00 (2.00–3.00) 2.00 (2.00–2.00) 2.00 (1.50–3.00) 2.00 (1.75–3.00) 2.00 (1.75–3.00) 2.00 (1.00–) 2.00 (2.00–3.00) 0.787 (0.044) − 0.392 (0.300) 0.479 (0.279) − 0.167 (0.731) 2.00 (2.00–3.00) 2.00 (2.00–2.25) 3.00 (2.00–3.00) 3.00 (3.00–3.00) 2.00 (2.00–2.00) 2.00 (2.00–3.00) 2.00 (2.00–2.75) 2.00 (1.50–3.00) 2.00 (1.75–3.00) 2.00 (1.00–3.00) 2.00 (2.00–2.00) 2.00 (2.00–3.00) 0.851 (0.035) − 0.305 (0.431) 0.874 (0.055) − 0.188 (0.706) 2.00 (1.00–2.00) 2.00 (1.00–2.25) 2.00 (2.00–3.00) 2.00 (2.00–3.00) 1.50 (1.00–3.00) 2.00 (2.00–3.00) 1.00 (1.00–2.00) 2.00 (2.00–3.00) 1.00 (1.00–2.00) 1.00 (1.00–2.00) 1.00 (1.00–) 2.00 (2.00–2.50) 1.047 (0.009) − 1.082 (0.006) 0.143 (0.747) 0.289 (0.555) 2.00 (2.00–2.00) 2.00 (1.00–2.00) 1.00 (1.00–2.00) 1.50 (1.00–2.25) 1.00 (1.00–1.00) 1.50 (1.00–2.25) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (0.00–1.00) 1.00 (0.75–1.00) 0.00 (0.00–0.00) 1.00 (1.00–2.00) 3.667 (< 0.001) − 0.839 (0.054) − 1.082 (0.039) − 1.383 (0.014) 2.00 (2.00–2.25) 2.00 (1.75–3.00) 2.00 (2.00–2.25) 2.00 (1.75–2.00) 2.00 (2.00–3.00) 2.00 (2.00–3.00) 2.00 (1.00–2.00) 2.00 (1.00–2.00) 1.50 (1.00–2.00) 2.00 (1.75–2.00) 2.00 (2.00–) 2.00 (1.50–2.00) 1.836 (< 0.001) − 0.039 (0.924) − 0.417 (0.393) 1.062 (0.054) 2.00 (1.75–2.25) 2.00 (2.00–3.00) 2.00 (1.75–2.00) 2.00 (1.75–2.00) 2.00 (2.00–2.00) 2.00 (2.00–3.00) 2.00 (1.00–2.00) 2.00 (1.00–2.00) 2.00 (1.00–2.25) 2.00 (1.00–2.00) 2.00 (2.00–2.00) 2.00 (1.00–2.00) 1.054 (0.014) − 0.287 (0.473) − 0.229 (0.621) 0.373 (0.475) 2.00 (1.75–2.00) 2.00 (1.75–3.00) 2.00 (2.00–2.25) 2.00 (2.00–3.00) 2.00 (2.00–3.00) 2.00 (2.00–3.00) 2.00 (1.00–2.00) 2.00 (2.00–2.00) 2.00 (1.00–2.00) 2.00 (1.00–2.00) 2.00 (2.00–2.00) 2.00 (1.50–2.00) 1.287 (0.005) − 0.358 (0.381) 0.415 (0.385) 0.516 (0.330) Data are expressed as median (interquartile range). P-values were derived from ordinal logistic regression. Significant values are in bold. ACE-2, angiotensin-converting enzyme 2; Gx, gonadectomy; HR, hormone replacement; TMPRSS-2, transmembrane protease serine 2. Impact of female reproductive history on ACE-2 and TMPRSS-2 expression. Data are expressed as median (interquartile range). P-values were derived from Mann–Whitney test. ACE-2, angiotensin-converting enzyme 2; TMPRSS-2, transmembrane protease serine 2.

Impact of age, sex, and myocardial injury on ACE-2 and TMPRSS-2 expression in lung tissue

In lung alveoli, sex was not associated with the expression level of ACE-2 and TMPRSS-2 under baseline conditions (p = 0.450 and p = 0.790, respectively) (Fig. 2A,B) and following ischemia–reperfusion injury (p = 0.300 and p = 0.924, respectively) (Fig. 3A,B).
Figure 2

ACE-2 and TMPRSS-2 immunoreactivity in lung alveoli in murine models of ageing and hormonal manipulation. The violin plots provide information on the full data distribution. The horizontal black line indicates the median of the kernel density plot. (A) ACE-2 immunoreactivity in young (left panel) and aged (right panel) control animals, gonadectomized animals, and gonadectomized animals receiving long-term hormone replacement. (B) TMPRSS-2 immunoreactivity in young (left panel) and aged (right panel) control animals, gonadectomized animals, and gonadectomized animals receiving long-term hormone replacement. Ordinal logistic regression was performed to test the association between the level of expression of ACE-2 and TMPRSS-2 with age, sex, and hormonal status. The resulting p-values are reported in the box. ACE-2, angiotensin-converting enzyme 2; Gx, gonadectomy; HR, hormone replacement; TMPRSS-2, transmembrane protease serine 2.

Figure 3

ACE-2 and TMPRSS-2 immunoreactivity in lung alveoli in a murine model of ageing, hormonal manipulation, and myocardial injury. The violin plots provide information on the full data distribution. The horizontal black line indicates the median of the kernel density plot. (A) ACE-2 immunoreactivity in young (left panel) and aged (right panel) control animals, gonadectomized animals, and gonadectomized animals receiving long-term hormone replacement following ischemia-reperfusion injury. (B) TMPRSS-2 immunoreactivity in young (left panel) and aged (right panel) control animals, gonadectomized animals and gonadectomized animals receiving long-term hormone replacement following ischemia-reperfusion injury. (C) Soluble angiotensin-converting enzyme (sACE-2) serum levels in young mice at baseline and following ischemia/reperfusion injury. Ordinal logistic regression was performed to test the association between the level of expression of ACE-2 and TMPRSS-2 with age, sex, and hormonal status. The resulting p-values are reported in the box. Unpaired Student’s t-test was applied for comparison of sACE-2 (only the significant p-value is reported). ACE-2, angiotensin-converting enzyme 2; Gx, gonadectomy; HR, hormone replacement; sACE-2, soluble angiotensin-converting enzyme; TMPRSS-2, transmembrane protease serine 2.

ACE-2 and TMPRSS-2 immunoreactivity in lung alveoli in murine models of ageing and hormonal manipulation. The violin plots provide information on the full data distribution. The horizontal black line indicates the median of the kernel density plot. (A) ACE-2 immunoreactivity in young (left panel) and aged (right panel) control animals, gonadectomized animals, and gonadectomized animals receiving long-term hormone replacement. (B) TMPRSS-2 immunoreactivity in young (left panel) and aged (right panel) control animals, gonadectomized animals, and gonadectomized animals receiving long-term hormone replacement. Ordinal logistic regression was performed to test the association between the level of expression of ACE-2 and TMPRSS-2 with age, sex, and hormonal status. The resulting p-values are reported in the box. ACE-2, angiotensin-converting enzyme 2; Gx, gonadectomy; HR, hormone replacement; TMPRSS-2, transmembrane protease serine 2. ACE-2 and TMPRSS-2 immunoreactivity in lung alveoli in a murine model of ageing, hormonal manipulation, and myocardial injury. The violin plots provide information on the full data distribution. The horizontal black line indicates the median of the kernel density plot. (A) ACE-2 immunoreactivity in young (left panel) and aged (right panel) control animals, gonadectomized animals, and gonadectomized animals receiving long-term hormone replacement following ischemia-reperfusion injury. (B) TMPRSS-2 immunoreactivity in young (left panel) and aged (right panel) control animals, gonadectomized animals and gonadectomized animals receiving long-term hormone replacement following ischemia-reperfusion injury. (C) Soluble angiotensin-converting enzyme (sACE-2) serum levels in young mice at baseline and following ischemia/reperfusion injury. Ordinal logistic regression was performed to test the association between the level of expression of ACE-2 and TMPRSS-2 with age, sex, and hormonal status. The resulting p-values are reported in the box. Unpaired Student’s t-test was applied for comparison of sACE-2 (only the significant p-value is reported). ACE-2, angiotensin-converting enzyme 2; Gx, gonadectomy; HR, hormone replacement; sACE-2, soluble angiotensin-converting enzyme; TMPRSS-2, transmembrane protease serine 2. Age did not have a significant impact on the level of ACE-2 expression in the lung alveoli at baseline condition (p = 0.225) (Fig. 2A). On the contrary, higher alveolar ACE-2 expression was associated with younger age following myocardial injury (p = 0.044) (Fig. 3A). Increasing age was associated with a lower expression of pulmonary TMPRSS-2 expression under baseline conditions (p = 0.001) and following myocardial injury (p < 0.001) (Figs. 2B and 3B). Similar observations were found for lung bronchioli (Tables 1 and 2). Circulating sACE-2 levels were significantly higher in females following ischemia–reperfusion injury as compared to males (p = 0.010, Fig. 3C), while this sex difference was not observed under baseline conditions (p = 0.520).

Impact of age, sex, and myocardial injury on ACE-2 and TMPRSS-2 expression in kidney, and hepatic tissues

In the kidney tubules, female sex was associated to a lower level of ACE-2 and TMPRSS-2 expression as compared to males following myocardial injury (p = 0.006) and at baseline condition (p = 0.014), respectively. In addition, following myocardial injury, Gx and Gx + HR therapy were associated with a lower extent of ACE-2 expression in the liver sinusoids as compared to the control group (p = 0.039 and p = 0.014, respectively). No additional age, sex, and hormonal status differences in the expression pattern of ACE-2 and TMPRSS-2 were observed in the remaining tissues and experimental groups (Tables 1 and 2). Younger age was associated with a higher level of ACE-2 expression in kidney tubules and liver sinusoids at baseline (p = 0.004 and p < 0.001, respectively, Table 1) and following myocardial injury (p = 0.009 and p < 0001, respectively, Table 2). Similarly, following myocardial injury, a higher level of expression of TMPRSS-2 in the kidney tubules was correlated with younger age (p = 0.005, Table 2).

Impact of sex and chronic pressure overload on ACE-2 and TMPRSS-2 expression in lung, kidney, and hepatic tissues

The distribution of ACE-2 and TMPRSS-2 expression level in female and male mice who underwent TAC surgery is reported in the Supplementary Information (Supplemental Table 1 and Supplemental Table 2). Statistical comparisons were not performed due to the small number of animals per group.

Impact of female reproductive history on ACE-2 and TMPRSS-2 expression

Female reproductive history did not impact pulmonary expression levels of ACE-2 and TMPRSS-2 as no difference in ACE-2 or TMPRSS-2 expression was observed in multiparous versus nulliparous mice (12 months old; Fig. 4A,B; Table 3). Multiparous mice had significantly higher progesterone levels as compared to nulliparous mice (p = 0.01, Fig. 4C) which is consistent with an increase in progesterone during pregnancy and shortly thereafter.
Figure 4

ACE-2 and TMPRSS-2 immunoreactivity in lung alveoli in murine models of pregnancy. The violin plots (A and B) provide information on the full data distribution. The horizontal black line indicates the median of the kernel density plot. (A) ACE-2 immunoreactivity in lung alveoli of 12 months-old multiparous and nulliparous mice. (B) TMPRSS-2 immunoreactivity in lung alveoli of 12 months-old multiparous and nulliparous mice. (C) Serum progesterone level in both groups. Mann–Whitney test was performed to compare the median of the tissue expression of ACE-2 and TMPRSS-2 between nulliparous and multiparous. Unpaired Student’s t-test was applied for comparison of progesterone levels. Only significant p-values are reported (more details in Table 3). ACE-2, angiotensin-converting enzyme 2; TMPRSS-2, transmembrane protease serine 2.

ACE-2 and TMPRSS-2 immunoreactivity in lung alveoli in murine models of pregnancy. The violin plots (A and B) provide information on the full data distribution. The horizontal black line indicates the median of the kernel density plot. (A) ACE-2 immunoreactivity in lung alveoli of 12 months-old multiparous and nulliparous mice. (B) TMPRSS-2 immunoreactivity in lung alveoli of 12 months-old multiparous and nulliparous mice. (C) Serum progesterone level in both groups. Mann–Whitney test was performed to compare the median of the tissue expression of ACE-2 and TMPRSS-2 between nulliparous and multiparous. Unpaired Student’s t-test was applied for comparison of progesterone levels. Only significant p-values are reported (more details in Table 3). ACE-2, angiotensin-converting enzyme 2; TMPRSS-2, transmembrane protease serine 2.

Discussion

Impact of sex on lung expression of ACE-2 and TMPRSS-2

Our experimental data indicate that gonadal hormones and biological sex do not alter the expression of membrane-bound ACE-2 and TMPRSS-2 in the respiratory tract in mice, independent of disease state. Previous data on ACE-2 and TMPRSS-2 expression in lung tissue have yielded conflicting results. Indeed, studies in both human and mouse tissue have reported higher, lower or similar ACE-2 expression in males as compared to females[29-32] as well as an upregulation (public genomics data) or downregulation (mRNA levels in bronchial epithelial cells) of ACE-2 by estrogen[33,34]. Similarly, while a recent mRNA sequencing study reports a higher TMPRSS-2 expression in men[35], previous studies did not detect such sex differences across different tissues[31,36]. Species differences, difficulties in precisely measuring membrane-bound ACE-2 expression and activity at the tissue level, confounding variables such as smoking[37] and obesity[38] as well as counter-regulatory effects of estrogens on the renin angiotensin system may have caused the high variability of available data. Several studies have reported the anti-inflammatory properties of progesterone, including inhibition of neutrophil degranulation and suppression of pro-inflammatory cytokine production[39]. As such, a recent pilot study has shown that subcutaneous administration of progesterone improved clinical status in 42 critically ill men infected with SARS-CoV-2[39]. However, the actions of progesterone on ACE-2 and TMPRSS-2 expression are currently unknown. Multiparous 12-months old mice in our study had significantly higher levels of progesterone than nulliparous mice while estrogen levels were low in both groups. Both ACE-2 and TMPRSS-2 expression did not differ between these two groups across various tissues. Therefore, our data support the hypothesis that the immunomodulatory actions of progesterone[40] rather than an effect of progesterone on SARS-CoV-2 receptor proteins may play a role in modulating COVID-19 disease course. Nevertheless, further studies addressing COVID-19 morbidity and mortality during pregnancy are needed given that the placenta and the uterus are important sources of ACE-2.

Impact of sex on ACE-2 and TMPRSS-2 expression in non-cardiac tissues

Pre-existing heart disease has been identified as a strong and independent predictor of adverse outcomes following SARS-CoV-2 infection[1]. Moreover, new cardiac complications are present in up to 12% of hospitalized COVID-19 patients[41]. Previous data suggests that myocardial ACE-2 expression is upregulated in cardiac dysfunction[42] with two studies reporting more pronounced alterations in males[43,44]. However, the impact of myocardial disease on ACE-2 expression in non-cardiac tissue is currently unknown. In our study, no sex difference in ACE-2 expression was observed in the experimental groups or organs evaluated with the exception of kidney tubules. This finding is consistent with the reports of two previous studies showing higher ACE-2 activity in male mouse kidneys as compared to females[45,46]. Overall, the interaction between male sex and CVD in predicting COVID-19 mortality seems independent of sex differences in ACE-2 expression levels. Differences in immune status associated with cardiovascular comorbidities offer potential alternative explanations for the bias towards male deaths in COVID-19.

Impact of age on ACE-2 and TMPRSS-2 expression

Age is another risk factor for both morbidity and mortality in COVID-19 patients, with children being mostly resistant to the effects of the SARS-CoV-2 virus. In our study, higher pulmonary TMPRSS-2 expression was associated with younger age at baseline condition and following myocardial injury and reperfusion. Similarly, higher TMPRSS-2 expression in kidney tubules was associated with younger age following myocardial injury. Age-dependent changes for alveolar ACE-2 were observed only following myocardial injury. These data contrast with the findings of higher ACE-2 and TMPRSS-2 expression with age reported in a recent study[35]. Species differences as well as differences between protein and gene expression levels may account for these inconsistent findings. Of note, other authors described higher sACE-2 serum levels in children as compared to adults[47] as well as a decreasing tubulointerstitial ACE-2 expression with age[48].

Conclusion

Taken together, sex differences in the expression of ACE-2 and TMPRSS-2 observed in mice may not explain the higher disease burden of COVID-19 among men and contrast with recently reported sex differences on the gene expression level in humans[35]. Further research into the applicability and translational value of preclinical models to study underlying disease mechanisms of COVID-19 is needed. Supplementary Information.
  42 in total

Review 1.  Renin angiotensin system and gender differences in the cardiovascular system.

Authors:  Marcus Fischer; Andrea Baessler; Heribert Schunkert
Journal:  Cardiovasc Res       Date:  2002-02-15       Impact factor: 10.787

2.  Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics.

Authors:  Christoph Muus; Malte D Luecken; Gökcen Eraslan; Lisa Sikkema; Avinash Waghray; Graham Heimberg; Yoshihiko Kobayashi; Eeshit Dhaval Vaishnav; Ayshwarya Subramanian; Christopher Smillie; Karthik A Jagadeesh; Elizabeth Thu Duong; Evgenij Fiskin; Elena Torlai Triglia; Meshal Ansari; Peiwen Cai; Brian Lin; Justin Buchanan; Sijia Chen; Jian Shu; Adam L Haber; Hattie Chung; Daniel T Montoro; Taylor Adams; Hananeh Aliee; Samuel J Allon; Zaneta Andrusivova; Ilias Angelidis; Orr Ashenberg; Kevin Bassler; Christophe Bécavin; Inbal Benhar; Joseph Bergenstråhle; Ludvig Bergenstråhle; Liam Bolt; Emelie Braun; Linh T Bui; Steven Callori; Mark Chaffin; Evgeny Chichelnitskiy; Joshua Chiou; Thomas M Conlon; Michael S Cuoco; Anna S E Cuomo; Marie Deprez; Grant Duclos; Denise Fine; David S Fischer; Shila Ghazanfar; Astrid Gillich; Bruno Giotti; Joshua Gould; Minzhe Guo; Austin J Gutierrez; Arun C Habermann; Tyler Harvey; Peng He; Xiaomeng Hou; Lijuan Hu; Yan Hu; Alok Jaiswal; Lu Ji; Peiyong Jiang; Theodoros S Kapellos; Christin S Kuo; Ludvig Larsson; Michael A Leney-Greene; Kyungtae Lim; Monika Litviňuková; Leif S Ludwig; Soeren Lukassen; Wendy Luo; Henrike Maatz; Elo Madissoon; Lira Mamanova; Kasidet Manakongtreecheep; Sylvie Leroy; Christoph H Mayr; Ian M Mbano; Alexi M McAdams; Ahmad N Nabhan; Sarah K Nyquist; Lolita Penland; Olivier B Poirion; Sergio Poli; CanCan Qi; Rachel Queen; Daniel Reichart; Ivan Rosas; Jonas C Schupp; Conor V Shea; Xingyi Shi; Rahul Sinha; Rene V Sit; Kamil Slowikowski; Michal Slyper; Neal P Smith; Alex Sountoulidis; Maximilian Strunz; Travis B Sullivan; Dawei Sun; Carlos Talavera-López; Peng Tan; Jessica Tantivit; Kyle J Travaglini; Nathan R Tucker; Katherine A Vernon; Marc H Wadsworth; Julia Waldman; Xiuting Wang; Ke Xu; Wenjun Yan; William Zhao; Carly G K Ziegler
Journal:  Nat Med       Date:  2021-03-02       Impact factor: 87.241

3.  Sex Hormones Promote Opposite Effects on ACE and ACE2 Activity, Hypertrophy and Cardiac Contractility in Spontaneously Hypertensive Rats.

Authors:  P L M Dalpiaz; A Z Lamas; I F Caliman; R F Ribeiro; G R Abreu; M R Moyses; T U Andrade; S A Gouvea; M F Alves; A K Carmona; N S Bissoli
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

4.  Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation.

Authors:  Jiawei Chen; Quanlong Jiang; Xian Xia; Kangping Liu; Zhengqing Yu; Wanyu Tao; Wenxuan Gong; Jing-Dong J Han
Journal:  Aging Cell       Date:  2020-06-19       Impact factor: 9.304

5.  Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2.

Authors:  Yuanyuan Qiao; Xiao-Ming Wang; Rahul Mannan; Sethuramasundaram Pitchiaya; Yuping Zhang; Jesse W Wotring; Lanbo Xiao; Dan R Robinson; Yi-Mi Wu; Jean Ching-Yi Tien; Xuhong Cao; Stephanie A Simko; Ingrid J Apel; Pushpinder Bawa; Steven Kregel; Sathiya P Narayanan; Gregory Raskind; Stephanie J Ellison; Abhijit Parolia; Sylvia Zelenka-Wang; Lisa McMurry; Fengyun Su; Rui Wang; Yunhui Cheng; Andrew D Delekta; Zejie Mei; Carla D Pretto; Shaomeng Wang; Rohit Mehra; Jonathan Z Sexton; Arul M Chinnaiyan
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-11       Impact factor: 11.205

6.  Targeting TMPRSS2 in SARS-CoV-2 Infection.

Authors:  Linda B Baughn; Neeraj Sharma; Eran Elhaik; Aleksandar Sekulic; Alan H Bryce; Rafael Fonseca
Journal:  Mayo Clin Proc       Date:  2020-07-19       Impact factor: 7.616

7.  Myocyte-Specific Upregulation of ACE2 in Cardiovascular Disease: Implications for SARS-CoV-2-Mediated Myocarditis.

Authors:  Nathan R Tucker; Mark Chaffin; Kenneth C Bedi; Irinna Papangeli; Amer-Denis Akkad; Alessandro Arduini; Sikander Hayat; Gökcen Eraslan; Christoph Muus; Roby P Bhattacharyya; Christian M Stegmann; Kenneth B Margulies; Patrick T Ellinor
Journal:  Circulation       Date:  2020-06-22       Impact factor: 29.690

8.  Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men.

Authors:  A Goren; C G Wambier; S Herrera; J McCoy; S Vaño-Galván; F Gioia; B Comeche; R Ron; S Serrano-Villar; P M Ramos; F A Cadegiani; M Kovacevic; A Tosti; J Shapiro; R Sinclair
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-10-21       Impact factor: 9.228

9.  Male gender is a predictor of higher mortality in hospitalized adults with COVID-19.

Authors:  Ninh T Nguyen; Justine Chinn; Morgan De Ferrante; Katharine A Kirby; Samuel F Hohmann; Alpesh Amin
Journal:  PLoS One       Date:  2021-07-09       Impact factor: 3.240

View more
  1 in total

Review 1.  Role of aging in Blood-Brain Barrier dysfunction and susceptibility to SARS-CoV-2 infection: impacts on neurological symptoms of COVID-19.

Authors:  Daniel Adesse; Luis Gladulich; Liandra Alvarez-Rosa; Michele Siqueira; Anne Caroline Marcos; Marialice Heider; Caroline Soares Motta; Silvia Torices; Michal Toborek; Joice Stipursky
Journal:  Fluids Barriers CNS       Date:  2022-08-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.